Protalix BioTherapeutics (NYSE:PLX - Get Free Report) had its price objective upped by equities research analysts at HC Wainwright from $10.00 to $15.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target indicates a potential upside of 457.62% from the company's current price. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.
Separately, StockNews.com lowered shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, January 24th.
Read Our Latest Analysis on PLX
Protalix BioTherapeutics Price Performance
NYSE PLX traded up $0.02 on Monday, reaching $2.69. 914,329 shares of the company's stock traded hands, compared to its average volume of 727,310. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.76. The stock has a 50-day simple moving average of $2.03 and a 200 day simple moving average of $1.44. The stock has a market cap of $198.06 million, a PE ratio of -20.69 and a beta of 0.75.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new stake in shares of Protalix BioTherapeutics in the 4th quarter worth about $35,000. XTX Topco Ltd bought a new position in Protalix BioTherapeutics in the third quarter worth about $36,000. Cubist Systematic Strategies LLC purchased a new stake in Protalix BioTherapeutics in the second quarter worth about $37,000. Sanctuary Advisors LLC bought a new stake in Protalix BioTherapeutics during the 3rd quarter valued at approximately $38,000. Finally, PFG Investments LLC purchased a new position in shares of Protalix BioTherapeutics during the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 16.53% of the company's stock.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Recommended Stories
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
